Health Care · Pharmaceutical Preparations · Nasdaq · CIK 318306 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $6.23Day +3.49%Mkt cap $355MP/E (FY) 6.2×1Y −7.7%Off 52W high −17.4%Vol (1Y) 52.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 2,525 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest23.2% of sh out |
| Days to cover8.3d |
| 13F net flow (QoQ)+4.46% |
| Top-10 13F concentration60.9% |
| Next report (est.)2026-08-12 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| P/E (FY)6.2× |
| Sales (TTM)$5.8M |
| Earnings (TTM)$66.1M |
| ROE70.0% |
| Net margin1223.1% |
| Debt / equity0.13× |
| Sales growth 3Y60.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+18.2% |
| 1Y−7.7% |
| 3Y+82.2% |
| 5Y−79.9% |
| 10Y−90.7% |
| Since incept. (ann.)−20.1% |
Total return through 2026-07-29 · series begins 2016-07-11. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)52.4% |
| Ann. volatility (3Y)68.7% |
| Sharpe (1Y)0.14 |
| Sharpe (3Y)0.66 |
| Max drawdown (1Y)−42.3% |
| Max drawdown (3Y)−63.5% |
| Beta (3Y vs SPY)1.80 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 5.0M | $22M | 8.80% | +1.0% |
| BlackRock, Inc. | 3.2M | $14M | 5.61% | +1.1% |
| AIGH Capital Management LLC | 3.1M | $14M | 5.44% | +55.0% |
| Cable Car Capital, LP | 3.0M | $13M | 5.28% | +20.3% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 2.7M | $12M | 4.70% | +0.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.2M | $10M | 3.80% | new |
| Propel Bio Management, LLC | 1.3M | $6M | 2.33% | +60.1% |
| KENNEDY CAPITAL MANAGEMENT LLC | 1.3M | $6M | 2.22% | +20.3% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-13 | −$0.30 | — | $8.7M | — |
| 2025-09-30 | 2025-11-12 | −$0.10 | — | — | — |
| 2025-06-30 | 2025-08-14 | $1.71 | — | $400,000 | — |
| 2025-03-31 | 2025-05-15 | −$0.24 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-12 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
License 58% · Product 42%
product & service · each slice's share of TAGGED segment revenue in the latest annual filing (XBRL, as filed). Untagged revenue is excluded from the denominator, so slices need not sum to consolidated sales.
